<p>In this episode, Dr. Nancy Smerkanich provides an update from the recent Vaccines and Related Biological Products Advisory Committee Meeting. The Advisory Committee Meeting lasted 9 hours and Emergency Use Authorizations continued to be a high priority topic throughout the discussion. </p>

In this episode, Dr. Nancy Smerkanich provides an update from the recent Vaccines and Related Biological Products Advisory Committee Meeting. The Advisory Committee Meeting lasted 9 hours and Emergency Use Authorizations continued to be a high priority topic throughout the discussion.

<p>In this episode, Dr. Nancy Smerkanich provides an update from the recent Vaccines and Related Biological Products Advisory Committee Meeting. The Advisory Committee Meeting lasted 9 hours and Emergency Use Authorizations continued to be a high priority topic throughout the discussion.&nbsp;</p>

Emergency Use Authorizations During the COVID-19 Pandemic - Part 3

Regulatory submission professionals talking about all things regulatory. 
-What's the latest on electronic regulatory submissions?
-What do I need to know about CDISC compliant data packages?
-What are most teams doing to support Ad Promo submissions in eCTD format?
We'll talk about trends, best practices, and emerging regulations. We'll also interview leaders from across the industry to share perspectives and lessons learned. 
Join us!

Business

Regulatory submission professionals talking about all things regulatory. -What's the latest on electronic regulatory submissions? -What do I need to know about CDISC compliant data packages? -What are most teams doing to support Ad Promo submissions in eCTD format? We'll talk about trends, best practices, and emerging regulations. We'll also interview leaders from across the industry to share perspectives and lessons learned. Join us!

Share Emergency Use Authorizations During the COVID-19 Pandemic - Part 3

Sign up to save your podcasts

Emergency Use Authorizations During the COVID-19 Pandemic - Part 3

Emergency Use Authorizations During the COVID-19 Pandemic - Part 3